The NHS and UK biotech company Genomics plc have announced a pilot study that aims to more accurately predict patients’ risk of heart disease using a new integrated polygenic and clinical risk tool.

• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities

Empowering Drug Discovery through Genomics

The NHS may soon be able to identify your risk of heart disease or a stroke well before it happens by studying your DNA.

• Genomics plc’s method outperforms current tools and could help save more than 2,000 lives annually in the US alone
• Opportunity to identify individuals who are at risk of heart disease and target immediate prevention

Genomics plc, a pioneering healthcare company that uses large-scale genetic information to develop innovative precision healthcare tools, is pleased to announce that it has successfully completed a $30m funding round. Some highlights include:
· Follows achievement of significant milestones in both its Precision Health and Therapeutics division
· Significant investment from leading life science investors Foresite Capital and F-Prime Capital
· Existing backers Oxford Sciences Innovation and Lansdowne Partners also participated
· Fundraise was oversubscribed
Genomics plc will use the funding to expand its work building a patient-centric, population health platform that unlocks a more proactive, precise and personalised form of healthcare.